MRZM (Marizyme) Mohanram G-Score: 3 (As of Sep. 2024) — Near Median


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Mohanram G-Score?

Marizyme MRZM -99.67% 12 Mohanram G-Score is 3 as of Sep. 2024, which is at its 10-year median of 3.00. GuruFocus rates MRZM with a GF Score™ of 12/100.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Marizyme has an G-score of 3.

The historical rank and industry rank for Marizyme's Mohanram G-Score or its related term are showing as below:

MRZM' s Mohanram G-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 3

During the past 13 years, the highest Piotroski G-score of Marizyme was 4. The lowest was 2. And the median was 3.

Marizyme  (OTCPK:MRZM) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Marizyme Mohanram G-Score Related Terms


Marizyme Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for Marizyme's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Mohanram G-Score Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 N/A 3.00 2.00 3.00

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 3.00 3.00 3.00

MRZM vs CNBX, XSNX, NBIO: Mohanram G-Score Comparison

For the Biotechnology subindustry, Marizyme's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme Mohanram G-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Marizyme's Mohanram G-Score falls into.


MRZM
12GF Score
Marizyme Inc MRZM
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Marizyme has an G-score of 3.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 3 mean?
Marizyme (MRZM) has a Mohanram G-Score of 3 as of Sep. 2024. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Marizyme and its competitors. This is near median its historical median of 3.00. Over the past decade, Marizyme's Mohanram G-Score has ranged from 2.00 to 4.00.
Is Marizyme's Mohanram G-Score too high?
Marizyme's current Mohanram G-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Mohanram G-Score compare to CNBX and XSNX?
Marizyme's Mohanram G-Score of 3 can be compared against companies in the Biotechnology industry. Historically, Marizyme's own Mohanram G-Score has ranged from 2.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Biotechnology company?
A good Mohanram G-Score depends on the Biotechnology industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Marizyme and its competitors. Marizyme's current Mohanram G-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Mohanram G-Score of 3. The current Mohanram G-Score is 3, which is near median its 10-year median of 3.00. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For Marizyme (MRZM), the current Mohanram G-Score is 3 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price